OSE Immunotherapeutics: FDA Grants Orphan Drug Designation to Anti-Rejection Treatment
OSE Immunotherapeutics announces that its partner Veloxis Pharmaceuticals has received orphan drug designation from the FDA for pegrizeprument (VEL-101) in the prevention of cardiac graft rejection. This recognition comes a few months after a similar designation was granted for liver transplantations.
Second Orphan Designation in Less than Four Months
Pegrizeprument, a monovalent monoclonal antibody fragment discovered and developed by OSE Immunotherapeutics, has received FDA orphan drug designation for the prophylaxis of cardiac allograft rejection. This designation follows the one granted in January 2026 for the prevention of organ rejection in patients undergoing liver transplantation. The drug has been licensed to Veloxis Pharmaceuticals since April 2021, which is responsible for global development, manufacturing, and future commercialization of the product for all transplantation-related indications.
Specific Immunomodulatory Mechanism of Action
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Pegrizeprument is a pegylated antibody fragment that binds to CD28 and blocks the co-stimulation of effector T cells by CD28, without blocking CTLA-4. This approach is intended to produce a dual mechanism of action: direct blocking of CD28-mediated T cell activation, combined with preserved immunosuppressive functions mediated by CTLA-4. The product is currently in development to prevent rejection following solid organ transplantation.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
